HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Goldlion Holdings (533 HK) Privatization - The Offer Price Is Acceptable

Shanghai Henlius Biotech (2696 HK) - LVC Increased Its Holding of Henlius Again

Shanghai Henlius Biotech (2696 HK)- LVC Is Betting on Higher Valuation Upside Due to Business Update

China Healthcare Weekly (Feb.16)-Update on CR Sanjiu's Acquisition of Tasly, the Impact of US Tariff

Equity Bottom-Up

<ul>
<li>Tam Jai's performance in recent years has been consistently below expectations. Its fundamentals have undergone negative changes after IPO. Consumers’ preference change may disrupt Tam Jai's business model.</li>
<li>Based on our forecast and the Cancellation Price of HK$1.58/share, P/E will be higher than the industry average. Considering the low trading liquidity and concerns on outlook, HK$1.58/share is acceptable.</li>
<li>The fundamentals/prospects of Tam Jai are different from the situation of Henlius' privatization.We recommend investors not reject the privatization easily because internationalization won’t bring significant positive changes in short term.</li>
</ul>


Tam Jai's performance in recent years has been consistently below expectations. Its fundamentals have undergone negative changes after IPO. Consumers’ preference change may disrupt Tam Jai's business model.
Based on our forecast and the Cancellation Price of HK$1.58/share, P/E will be higher than the industry average. Considering the low trading liquidity and concerns on outlook, HK$1.58/share is acceptable.
The fundamentals/prospects of Tam Jai are different from the situation of Henlius' privatization.We recommend investors not reject the privatization easily because internationalization won’t bring significant positive changes in short term.


Tam Jai International (2217 HK) Privatization - The Offer Price Is Good